Clinical Heterogeneity and Transitions of Obesity in Mexico.

IF 5.1 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Adrian Soto-Mota, Rodrigo M Carrillo-Larco, Edward Gregg, Rosalba Rojas-Martínez, Majid Ezzati, Carlos Aguilar-Salinas
{"title":"Clinical Heterogeneity and Transitions of Obesity in Mexico.","authors":"Adrian Soto-Mota, Rodrigo M Carrillo-Larco, Edward Gregg, Rosalba Rojas-Martínez, Majid Ezzati, Carlos Aguilar-Salinas","doi":"10.1210/clinem/dgaf158","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated comorbidities are lacking.</p><p><strong>Objective: </strong>We estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years.</p><p><strong>Methods: </strong>We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS), which assesses 3 dimensions (medical, mental, and functional) across 5 incremental severity stages, by sex and age groups, were estimated across all included surveys. Metabolically healthy obesity (MHO) was defined as the absence of diabetes, dyslipidemia, and hypertension.</p><p><strong>Results: </strong>A total of 20 758 participants were analyzed. Mean body mass index (BMI) increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among MHO individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, MHO was less likely as age and BMI increased.</p><p><strong>Conclusion: </strong>The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the aging of the population will cause additional burdens to the population and the health system.</p>","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e3648-e3655"},"PeriodicalIF":5.1000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617558/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf158","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Context: There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated comorbidities are lacking.

Objective: We estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years.

Methods: We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS), which assesses 3 dimensions (medical, mental, and functional) across 5 incremental severity stages, by sex and age groups, were estimated across all included surveys. Metabolically healthy obesity (MHO) was defined as the absence of diabetes, dyslipidemia, and hypertension.

Results: A total of 20 758 participants were analyzed. Mean body mass index (BMI) increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among MHO individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, MHO was less likely as age and BMI increased.

Conclusion: The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the aging of the population will cause additional burdens to the population and the health system.

墨西哥肥胖的临床异质性和转变。多个代表性全国调查的纵向分析。
背景:个体发生肥胖相关合并症的风险存在很大差异。虽然肥胖在墨西哥非常普遍,但缺乏有关其相关合并症的程度和异质性的数据。因此,我们估计了不同肥胖相关合并症的患病率,以及它们在15年内的变化情况。方法:我们收集了2006年至2022年全国代表性健康与营养调查(ENSANUT)不同版本的数据。在埃德蒙顿肥胖分期系统(EOSS)中,肥胖的患病率以及与糖尿病、血脂异常、高血压、抑郁和行动障碍共存的结果,该系统评估了三个维度(医疗、精神和功能),跨越五个渐进的严重程度阶段,按性别和年龄组在所有纳入的调查中进行估计。代谢健康的肥胖被定义为没有糖尿病、血脂异常和高血压。结果:分析了20758名参与者。在调查期间,所有年龄段的平均BMI从30.2逐渐增加到31.0。即使在代谢健康的肥胖个体中,抑郁和活动能力受损也非常普遍。虽然大多数肥胖患者至少有一种可检测到的异常,但所呈现的合并症存在很大的异质性。最常见的EOSS类别是医学维度的第2阶段(90.1%),功能和精神维度的第1阶段(分别为75.1%和62.9%)。肥胖相关合并症的患病率随着年龄的增长而增加,但在所有调查中都是相似的。在两性中,随着年龄和体重指数的增加,代谢健康型肥胖的可能性更小。结论:墨西哥肥胖合并症的患病率一直保持稳定,但随着年龄的增长而增加。肥胖流行率的上升和人口老龄化将给人口和卫生系统带来额外负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Endocrinology & Metabolism
Journal of Clinical Endocrinology & Metabolism 医学-内分泌学与代谢
CiteScore
11.40
自引率
5.20%
发文量
673
审稿时长
1 months
期刊介绍: The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信